Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology

额颞叶变性 陶氏病 医学 生物标志物 脑脊液 慢性创伤性脑病 病理 失智症 τ蛋白 尸检 皮质基底变性 阿尔茨海默病 基因亚型 接收机工作特性 Tau病理学 诊断生物标志物 疾病 内科学 肿瘤科 痴呆 免疫组织化学 队列 进行性核上麻痹 磁共振成像 发病机制 S
作者
Kanta Horie,Rama K. Koppisetti,Lawren VandeVrede,Breton Michael Asken,Yan Li,Daniel Yen,Nupur Ghoshal,Ross W. Paterson,Argentina Lario Lago,William W. Seeley,Lea T. Grinberg,Randall John Bateman,Adam L Boxer,Salvatore Spina,Chihiro Sato
出处
期刊:JAMA [American Medical Association]
标识
DOI:10.1001/jama.2026.24689
摘要

Importance: Neurodegenerative diseases with abnormal tau protein aggregation in the brain (ie, tauopathies) can be classified by the tau isoform that accumulates: 3-repeat (3R), 4-repeat (4R), or mixed 3R/4R tauopathies, which include chronic traumatic encephalopathy (CTE), some forms of frontotemporal lobar degeneration, and Alzheimer disease (AD). The endogenously cleaved form of tau microtubule binding region containing the residue 243 (eMTBR-tau243) can be detected in cerebrospinal fluid (CSF) and blood and has been associated with AD tau pathology, but its specificity and biological interpretation in non-AD tauopathies remains unclear. Objective: To evaluate biofluid eMTBR-tau243 in a range of tauopathies. Design, Setting, and Participants: This case-control study included 4 biorepositories based in the US that contributed CSF and plasma samples from participants with and without tauopathies, many of whom had antemortem biofluid samples paired with autopsy or genetically defined neuropathology. Samples were analyzed between August 2023 and December 2025. Data analysis occurred from August 2024 to July 2026. Exposure: CSF and plasma eMTBR-tau243 concentrations measured using a mass spectrometry-based assay. Main Outcomes and Measures: Outcomes included mixed 3R/4R tauopathy (eg, AD and CTE) based on autopsy, frontotemporal lobar degeneration with MAPT variants (FTLD-MAPT), and CTE stage. Differences in biomarker levels between groups were evaluated using analysis of variance or analysis of covariance, and area under the receiver operating characteristic curve (AUC) was calculated to evaluate the discriminative performance of fluid eMTBR-tau243. Results: Among the 229 participants (196 with CSF samples and 55 with plasma samples [22 with both]), mean (SD) age at fluid sample collection was 63 (13) years and 108 (47%) were female. Median (IQR) CSF eMTBR-tau243 was increased in 10 patients with AD (0.459 [0.246-0.801] fmol/mL) compared with 29 cognitively unimpaired controls (0.002 [0.001-0.005] fmol/mL) (adjusted P < .001), but other autopsy-confirmed non-AD tauopathies (which included 52 individuals with conditions including progressive supranuclear palsy and corticobasal degeneration) did not demonstrate an increase (0.015 [0.008, 0.039] fmol/mL). Six symptomatic FTLD-MAPT variant carriers with mixed 3R/4R tauopathy (R406W, V337M, and G389R) had increased median (IQR) CSF eMTBR-tau243 (0.140 [0.055-0.174] fmol/mL) compared with 15 4R tauopathy variant carriers including N279K and P301L (0.004 [0.001-0.044] fmol/mL) (P = .001). Median (IQR) plasma eMTBR-tau243 was increased in 11 patients with CTE (1.93 [0.42-3.68] fmol/L) compared with 20 cognitively unimpaired controls (0.29 [0.05-0.62] fmol/L) (adjusted P = .007), but did not increase as high as among 14 patients with AD (11.25 [2.29-19.38] fmol/L). Plasma eMTBR-tau243 distinguished CTE stage III and IV from controls (AUC, 0.97; 95% CI, 0.92-1.00), but not CTE stage I from controls (AUC, 0.64; 95% CI, 0.32-0.97). Conclusions and Relevance: This study found that plasma and CSF eMTBR-tau243 were increased in mixed 3R/4R tauopathies including AD, high-stage CTE, and a subset of genetic FTLD-MAPT, compared with cognitively unimpaired controls. Further validation in larger cohorts is needed to determine the clinical utility of eMTBR-tau243 as a potential diagnostic biomarker for CTE and other tauopathies beyond AD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
zzyy完成签到,获得积分10
1秒前
Akim的应助被Zx采纳,获得10
2秒前
木头发布了新的文献求助10
2秒前
CodeCraft的应助被木夫贝采纳,获得10
2秒前
香蕉觅云的应助被阿冲采纳,获得10
2秒前
3秒前
失眠小懒虫完成签到,获得积分10
3秒前
打打的应助被shiv采纳,获得50
3秒前
4秒前
XPR发布了新的文献求助10
4秒前
4秒前
希望天下0贩的0的应助被精一采纳,获得10
5秒前
yize完成签到,获得积分10
7秒前
所所的应助被体贴的小馒头采纳,获得10
8秒前
刘亦然完成签到 ,获得积分10
8秒前
小马甲的应助被明前易拉罐采纳,获得10
8秒前
9秒前
川一发布了新的文献求助10
9秒前
我是老大的应助被coco采纳,获得10
10秒前
可爱的函函的应助被yize采纳,获得10
11秒前
科勒的黑猩猩完成签到 ,获得积分10
12秒前
所所的应助被栗子砸采纳,获得10
12秒前
efficient发布了新的文献求助10
13秒前
13秒前
xiaobuding完成签到,获得积分10
14秒前
丘比特的应助被路小雨采纳,获得10
14秒前
15秒前
云起完成签到 ,获得积分10
15秒前
耍酷巨人完成签到,获得积分10
15秒前
16秒前
诚心面包发布了新的文献求助10
17秒前
17秒前
哈哈哈发布了新的文献求助20
17秒前
18秒前
18秒前
18秒前
wwwwwwww完成签到,获得积分10
19秒前
benlaron发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621